Format

Send to

Choose Destination
Curr Opin Genet Dev. 2018 Feb;48:22-29. doi: 10.1016/j.gde.2017.10.003. Epub 2017 Nov 5.

Ribosome biogenesis and cancer: basic and translational challenges.

Author information

1
Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Campus Unamuno s/n, 37007 Salamanca, Spain.
2
Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Campus Unamuno s/n, 37007 Salamanca, Spain; Departamento de Bioquímica y Biología Molecular, University of Salamanca, Campus Unamuno s/n, 37007 Salamanca, Spain. Electronic address: mdosil@usal.es.

Abstract

Increasing evidence suggests that alterations in ribosome biogenesis (RiBi) confer competitive advantages to cancer cells. This has led to the discovery of regulatory layers mediated by signaling proteins, oncoproteins, and tumor suppressors whose deregulation leads to increased RiBi rates in cancer cells. In addition to boosting protein synthesis, these alterations probably contribute to shape the protumorigenic proteome of cancer cells. Mutations negatively affecting RiBi are also unexpectedly found in some spontaneous and ribosomopathy-associated tumors. The advantages provided by these genetic lesions to cancer cells remain unsettled as yet. Efforts are being made nowadays to exploit RiBi-associated vulnerabilities and tumor suppressor pathways to design new therapeutic avenues. In this review, we will summarize the main developments and pending challenges in this research area.

PMID:
29100209
DOI:
10.1016/j.gde.2017.10.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center